Duquesne Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-88,910
| Closed | -$21.1M | – | 49 |
|
|
2022
Q4 | $21.1M | Hold |
88,910
| – | – | 1.05% | 20 |
|
|
2022
Q3 | $17.8M | Buy |
+88,910
| New | +$17.8M | 1.01% | 25 |
|
|
2022
Q2 | – | Sell |
-63,945
| Closed | -$10.4M | – | 43 |
|
|
2022
Q1 | $10.4M | Buy |
+63,945
| New | +$10.4M | 0.45% | 26 |
|
|
2020
Q4 | – | Sell |
-368,419
| Closed | -$53.6M | – | 55 |
|
|
2020
Q3 | $53.6M | Hold |
368,419
| – | – | 1.56% | 18 |
|
|
2020
Q2 | $54.6M | Hold |
368,419
| – | – | 1.67% | 19 |
|
|
2020
Q1 | $40.1M | Buy |
368,419
+252,250
| +217% | +$27.5M | 1.63% | 17 |
|
|
2019
Q4 | $13.4M | Buy |
+116,169
| New | +$13.4M | 0.39% | 38 |
|